US scientists to explore potential of antibody against Long Covid
US scientists are undertaking a clinical trial to decode the efficacy of a long-acting antibody against Long Covid -- a condition that affects at least 65 million people worldwide.
Long Covid affects people after an infection caused by the SARS-CoV-2 virus. The condition not properly defined yet presents with more than 200 symptoms.
The team from the Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC) announced that a clinical trial is underway to assess the effectiveness and safety of sipavibart -- a long-acting monoclonal antibody designed by British drugmaker AstraZeneca’s to protect the condition.
The team enrolled 100 patients in the multi-year research, reviewed and cleared by the FDA earlier this year. It aims to improve patients Long Covid sympto...










